Stellest Lenses Receive FDA Approval: A Breakthrough in Myopia Control for Children

Introduction

Myopia, also known as nearsightedness, is one of the fastest-growing vision problems in children today. Studies show that nearly half of the world’s population may be myopic by 2050, and children who develop myopia at an early age are more likely to progress to high myopia, increasing the risk of eye diseases later in life.

The good news? A new innovation is now available in the United States. In September 2025, the U.S. Food and Drug Administration (FDA) officially authorized the Essilor Stellest® lens—the first spectacle lens in the U.S. clinically proven to slow the progression of myopia in children.

This is a historic moment in pediatric eye care and a major step forward in protecting children’s long-term vision.

What Are Stellest Lenses?

The Stellest lens looks like a regular pair of eyeglass lenses but is designed with a groundbreaking technology to do more than just correct blurry distance vision.

• Clear central vision zone – Provides sharp vision like traditional glasses.

• Unique lenslets technology – Hundreds of tiny lenslets arranged in a specific pattern around the central zone create a “myopia control signal” that slows down how quickly the eye grows in length.

• Proven effectiveness – Stellest lenses are clinically shown to slow myopia progression by up to 71% over two years compared to single-vision lenses.

Unlike contact lenses or eye drops, Stellest works through a simple pair of glasses that children wear every day, making it an easy and safe option for families.

FDA Approval: Why It Matters

The FDA granted Stellest lenses market authorization for children between the ages of 6 and 12 years old at the start of treatment. This means U.S. eye doctors can now prescribe Stellest to young patients who are developing myopia.

Clinical studies reviewed by the FDA showed that children wearing Stellest lenses experienced:

• 71% less myopia progression compared to single-vision lenses.

• 53% slower eye growth (axial elongation) after two years of wear.

• No serious safety concerns, with only minor adaptation issues like glare or halos reported in some cases.

Long-Term Research on Stellest Lenses

The FDA’s approval is supported not just by short-term studies, but also by long-term clinical data. A six-year research study in China confirmed that Stellest lenses continue to slow myopia progression by nearly 2.00 diopters and reduce eye growth by more than 50% compared to controls.

This is important because slowing myopia by even 1.00 diopter can significantly lower a child’s lifetime risk of retinal detachment, glaucoma, or vision loss later in life.

Benefits for Families

Stellest lenses are a game-changer for families looking to protect their child’s vision:

1. Easy to wear – Works just like a pair of glasses.

2. Safe for young children – No need to worry about contact lens hygiene or infections.

3. Starts early – Authorized for children as young as 6 years old.

4. Proven results – Backed by years of clinical studies worldwide.

Considerations for Parents

While Stellest lenses are an exciting breakthrough, there are a few things parents should know:

• Children may notice halos or slight blur when first adapting to the lenses.

• Consistent daily wear is essential for best results.

• Cost and insurance coverage may vary depending on your vision plan.

• Not every prescription range may be available right away as the lenses launch in the U.S.

Why This FDA Approval Is a Milestone

For years, parents in the U.S. have had limited options for myopia control—mostly specialty contact lenses or low-dose atropine drops. Stellest lenses finally give families a non-invasive, glasses-based solution backed by the FDA and trusted worldwide.

This means eye doctors can now offer multiple treatment choices tailored to each child’s needs, making myopia management more accessible than ever.

Conclusion

The FDA’s approval of Stellest lenses marks a new era in pediatric eye care. For the first time, U.S. children have access to an FDA-authorized spectacle lens clinically proven to slow the progression of myopia.

As myopia rates continue to rise, Stellest offers parents peace of mind and children a brighter, clearer future with healthier eyes.

If your child is becoming nearsighted or you want to learn more about myopia control options like Stellest lenses, schedule a comprehensive pediatric eye exam with our office today.

References

1. U.S. Food and Drug Administration. FDA Authorizes Marketing of First Eyeglass Lenses to Slow Progression of Pediatric Myopia. 2025.

2. EssilorLuxottica. Press Release: FDA Authorization of Stellest Lenses. September 2025.

3. Optometry Times. Essilor Stellest Authorized in the U.S. for Myopia Control. 2025.

4. Contemporary Pediatrics. FDA Authorizes Essilor Stellest for Children 6–12 Years Old. 2025.

5. Review of Myopia Management. Six-Year Data on Stellest Lenses. 2024.